Craig-Hallum analyst Matt Hewitt lowered his price target for Teladoc to $70 from $80, while reiterating a Buy rating on the shares. The analyst views Q1 as a “solid” quarter that highlights the diversification of Teladoc’s revenue model, noting that despite flu volumes being down 32% year over year revenue grew by 23% organically, which enabled essentially in-line results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.